License to Ambrx Under BMS Improvements to Ambrx ReCODE/EuCODE Technology Sample Clauses

License to Ambrx Under BMS Improvements to Ambrx ReCODE/EuCODE Technology. Subject to and without limiting the other terms and conditions of this Agreement, BMS hereby grants to Ambrx a fully paid-up, royalty-free non-exclusive license under the BMS Improvement Patents solely for use in the expression/production of proteins made using the Ambrx ReCODE/EuCODE Technology. Such license may be sublicensed together with other Ambrx technology only to the extent as set forth below, and shall otherwise be non-transferable. “BMS Improvement Patents” means Patents Controlled by BMS (and only such Patents to the extent that BMS has the right to grant to Ambrx the license under such Patents as set forth in this Section 7.3(b) without any payment obligation or conflict with any other obligation to any Third Party) claiming inventions made during the Term by BMS that are improvements to the Ambrx ReCODE/EuCODE Technology for the expression of proteins using the Ambrx ReCODE/EuCODE Technology, where such inventions are made based upon or through use of the confidential Ambrx Know-How, Ambrx Materials and/or Ambrx Confidential Information. For clarification, the rights granted to Ambrx by BMS under this Section 7.3(b) are limited to the BMS Improvement Patents and no rights are granted under any other Patents Controlled by BMS. Ambrx’s rights to sublicense a Third Party (a “Licensee”) under the nonexclusive rights granted by BMS to Ambrx under this Section 7.3(b) shall be further limited as follows. The Licensee’s rights with respect to rights granted by BMS to Ambrx under Section 7.3(b) shall be limited to and shall not exceed the scope of the corresponding rights (if any) that such Licensee has granted back to Ambrx (including any limitations and restrictions with respect to such rights) and that are effectively sublicensed to BMS hereunder without additional fee. Accordingly, if the scope of such Licensee rights granted back to Ambrx (and effectively sublicensed to BMS hereunder) is narrower in whole or in part and/or any restrictions with respect to such sublicense are more restrictive in whole or in part than the corresponding scope and restrictions set forth in Section 7.3(b), then the rights granted back to Ambrx under Section 7.3(b) that Ambrx has the right to sublicense to such Licensee shall be limited to be more restrictive and to have a narrower scope so as to correspond to the restrictions and scope of such rights granted back to Ambrx by the License (and effectively sublicensed to BMS hereunder).
AutoNDA by SimpleDocs

Related to License to Ambrx Under BMS Improvements to Ambrx ReCODE/EuCODE Technology

  • Background Technology List here prior contracts to assign Inventions that are now in existence between any other person or entity and you. [ ] List here previous Inventions which you desire to have specifically excluded from the operation of this Agreement. Continue on reverse side if necessary.

  • Licensed Technology The term "Licensed Technology" shall mean the ------------------- Licensed Patents, plus all improvements thereto developed by Licensor, and all related data, know-how and technology.

  • Know-How The term “

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Background IP Each Party will own all right, title and interest in its Background IP.

  • Know-How Royalty Notwithstanding the provisions of Section 5.4.1(a), in countries where the sale of Product by Merck or its Related Parties would not infringe a Valid Patent Claim, Merck shall pay royalty rates that shall be set at [***] of the applicable royalty rate determined according to Section 5.4.1(a). Such royalties shall be calculated after first calculating royalties under Section 5.4.1(a).

  • Third Party Technology The assignment of any applicable license agreements with respect to Third Party Technology are set forth in the General Assignment and Assumption Agreement.

  • New Technology If New Technology becomes available from any source, including Supplier, then KP may evaluate and contract with any supplier so that KP will have access to New Technology at all times. If Supplier cannot offer New Technology at comparable or lower prices, KP may either (a) amend contract pricelist to add Supplier's New Technology at a mutually agreed-upon price; or (b) contract with other suppliers for New Technology. Regardless of whether New Technology is added to this Agreement, Supplier and KP will negotiate in good faith to equitably adjust the pricing for any current Product under this Agreement affected by the New Technology.

  • Rights to Work Product The Employee agrees that all work performed by the Employee pursuant hereto shall be the sole and exclusive property of the Company, in whatever stage of development or completion. With respect to any copyrightable works prepared in whole or in part by the Employee pursuant to this Agreement, including compilations of lists or data, the Employee agrees that all such works will be prepared as “work-for-hire” within the meaning of the Copyright Act of 1976, as amended (the “Act”), of which the Company shall be considered the “author” within the meaning of the Act. In the event (and to the extent) that such works or any part or element thereof is found as a matter of law not to be a “work-for-hire” within the meaning of the Act, the Employee hereby assigns to the Company the sole and exclusive right, title and interest in and to all such works, and all copies of any of them, without further consideration, and agrees, to the extent reasonable under the circumstances, to cooperate with the Company to register, and from time to time to enforce, all patents, copyrights and other rights and protections relating to such works in any and all countries. To that end, the Employee agrees to execute and deliver all documents requested by the Company in connection therewith, and the Employee hereby irrevocably designates and appoints the Company as the Employee’s agent and attorney-in-fact to act for and on behalf of the Employee and in the Employee’s stead to execute, register and file any such applications, and to do all other lawfully permitted acts to further the registration, protection and issuance of patents, copyrights or similar protections with the same legal force and effect as if executed by the Employee. The Company shall reimburse the Employee for all reasonable costs and expenses incurred by the Employee pursuant to this Section 11.

  • Development License A non-transferable (except as provided in Section 17.1 (Assignment)), sublicensable (subject to Section 11.2.5 (Voyager Sublicense Rights)), worldwide, non-exclusive, royalty-free license under the Genzyme Technology, Genzyme Collaboration Technology and Genzyme’s interest in the Joint Collaboration Technology to (a) Develop the Split Territory Licensed Products and conduct such Split Territory Licensed Program inside and outside the Voyager Territory for Commercialization of such Split Territory Agreement Products in the Field in the Voyager Territory, and (b) Manufacture the Split Territory Licensed Products inside or outside of the Voyager Territory for the purposes of such Development, in each case (a) and (b) as and to the extent set forth in any Global Development Plan or Voyager Territory Development Plan.

Time is Money Join Law Insider Premium to draft better contracts faster.